

# Evaluation of statin prescriptions in type 2 diabetes: India Heart Watch-2

Rajeev Gupta,<sup>1</sup> Sailesh Lodha,<sup>1</sup> Krishna K Sharma,<sup>2</sup> Surendra K Sharma,<sup>3</sup> Sunil Gupta,<sup>4</sup> Arthur J Asirvatham,<sup>5</sup> Bhupendra N Mahanta,<sup>6</sup> Anuj Maheshwari,<sup>7</sup> Dinesh C Sharma,<sup>8</sup> Anand S Meenawat,<sup>9</sup> Raghubir S Khedar<sup>1</sup>

**To cite:** Gupta R, Lodha S, Sharma KK, *et al*. Evaluation of statin prescriptions in type 2 diabetes: India Heart Watch-2. *BMJ Open Diabetes Research and Care* 2016;4:e000275. doi:10.1136/bmjdr-2016-000275

Received 27 May 2016  
Revised 20 July 2016  
Accepted 27 July 2016

## ABSTRACT

**Background:** Contemporary treatment guidelines advise statin use in all patients with diabetes for reducing coronary risk. Use of statins in patients with type 2 diabetes has not been reported from India. **Methods:** We performed a multisite (n=9) registry-based study among internists (n=3), diabetologists (n=3), and endocrinologists (n=3) across India to determine prescriptions of statins in patients with type 2 diabetes. Demographic and clinical details were obtained and prescriptions were audited for various medications with a focus on statins. Details of type of statin and dosage form (low, moderate, and high) were obtained. Patients were divided into categories based on presence of cardiovascular risk into low (no risk factors, n=1506), medium ( $\geq 1$  risk factor, n=5425), and high (with vascular disease, n=1769). Descriptive statistics are presented.

**Results:** Prescription details were available in 8699 (men 5292, women 3407). Statins were prescribed in 55.2% and fibrates in 9.2%. Statin prescription was significantly greater among diabetologists (64.4%) compared with internists (n=53.3%) and endocrinologists (46.8%;  $p < 0.001$ ). Atorvastatin was prescribed in 74.1%, rosuvastatin in 29.2%, and others in 3.0%. Statin prescriptions were lower in women (52.1%) versus men (57.2%;  $p < 0.001$ ) and in patients aged  $< 40$  years (34.3%), versus those aged 40–49 (49.7%), 50–59 (60.1%), and  $\geq 60$  years (62.2%;  $p < 0.001$ ). Low-dose statins were prescribed in 1.9%, moderate dose in 85.4%, and high dose in 12.7%. Statin prescriptions were greater in the high-risk group (58.0%) compared with those in the medium-risk (53.8%) and low-risk (56.8%) groups ( $p < 0.001$ ). High-dose statin prescriptions were similar in the high-risk (14.5%), medium-risk (11.8%), and low-risk (13.5%) groups ( $p = 0.31$ ).

**Conclusions:** Statins are prescribed in only half of the clinic-based patients in India with type 2 diabetes. Prescription of high-dose statins is very low.

## INTRODUCTION

Diabetes is an epidemic in India.<sup>1</sup> It is also associated with a greater prevalence of macrovascular and microvascular disease and these patients have a higher long-term mortality as compared with patients in developed countries.<sup>2–3</sup> Multiple factors are responsible

## Key messages

- There are no contemporary data on statin prescriptions among patients with type 2 diabetes in India.
- In a multisite study in India, we observed sub-optimal prescription of statins in patients with diabetes. A prescription of high-dose statins was low in all patients with diabetes, including those at high risk.
- Statin prescriptions were significantly less by endocrinologists and physicians compared with diabetologists.

for greater morbidity and mortality from diabetes in India and include low awareness, treatment, and control of glycemia in patients with diabetes.<sup>4–5</sup> Greater prevalence and low awareness, treatment, and control of cardiovascular risk factors (smoking, hypertension, dyslipidemia, and unhealthy lifestyles), especially in lower socioeconomic status patients, is also important.<sup>6</sup>

Control of cardiovascular risk factors such as hypertension and hypercholesterolemia in patients with diabetes can prevent complications. It has been reported that appropriate use of statins can prevent symptomatic coronary heart disease as well as acute coronary events in patients with type 2 diabetes in all populations including South Asians.<sup>7–8</sup> Patients with type 2 diabetes have a long-term risk of cardiovascular mortality similar to patients without diabetes and overt cardiovascular disease.<sup>8–12</sup> Based on these epidemiological observations and primary prevention trials, many international guidelines recommend routine use of statins in patients with type 2 diabetes.<sup>8–15</sup> The American College of Cardiology/American Heart Association (ACC/AHA) 2013 statement classified diabetes as a coronary risk equivalent and recommended high-dose statin therapy in all patients with diabetes.<sup>8</sup> Diabetes registries in developed countries, for example, the Swedish National Diabetes Register, have reported a high use of statins



CrossMark

For numbered affiliations see end of article.

**Correspondence to**  
Dr Rajeev Gupta;  
rajeevgg@gmail.com

in patients with type 2 diabetes.<sup>16</sup> No similar data are available from developing countries, including India. Previous studies that reported treatment patterns in type 2 diabetes in India were published before the recent recommendations<sup>17–20</sup> and a review reported suboptimal quality of diabetes management in India.<sup>21</sup> Therefore, to document the extent of prescriptions of statins and their types in patients with type 2 diabetes and to correlate this with vascular risk status of these patients, we performed a multisite registry-based study.

## METHODS

We performed a multisite (n=9) registry-based study in eight cities across India to determine the prescription pattern of statins in patients with type 2 diabetes. The Institutional Ethics Committee at the central coordinating center at Jaipur, India, approved the study. Requirement of informed consent from each patient was waived by the Ethics Committee because anonymized data were used for analyses. We obtained data on successive patients attending the outpatient department at respective centers until the target of 500 patients was reached at each site. A larger sample size was available at the primary site where the pro forma was piloted.<sup>20</sup>

Demographic and clinical details were obtained that were similar to the previous India Heart Watch study.<sup>4</sup> An abbreviated version useful for a disease registry was used in the present study.<sup>20</sup> Sociodemographic factors were education, occupation, and socioeconomic status and lifestyle factors included details of smoking and tobacco use, physical activity patterns and diet. Details of concomitant risk factors—overweight or obesity (body mass index  $\geq 25$  kg/m<sup>2</sup>), hypertension, hypercholesterolemia (total cholesterol  $\geq 200$  mg/dL), hypertriglyceridemia (triglycerides  $\geq 150$  mg/dL), and low high-density lipoprotein (HDL) cholesterol (<40 mg/dL in men, <50 mg/dL in women)—as well as duration of diabetes were also obtained. Presence of microvascular diseases was ascertained from medical records with a focus on diabetic retinopathy, chronic renal disease (serum creatinine  $\geq 2.0$  mg/dL), and overt diabetic foot disease. We did not obtain details of the presence of microalbuminuria, proteinuria, albumin–creatinine ratio, or ankle–brachial index due to lack of uniform data at all sites. Presence of macrovascular disease was obtained from the patients and included history of overt coronary heart disease, history of stroke, or symptomatic peripheral arterial disease with claudication.

Physicians were divided by specialization into specific type of care provider as internists (n=3), diabetologists (internists with primary interest in diabetes, n=3), and board-certified endocrinologists (n=3). Patients were also subdivided accordingly into internists (n=2301), diabetologists (n=3299), and endocrinologists (n=3099). Patients were also categorized based on the presence of cardiovascular risk into low, medium, and high risk. Risk factors other than diabetes were used in classification

and were either smoking or tobacco use, hypertension, or hypercholesterolemia. Details of overt microvascular disease (retinopathy, chronic renal failure, serum creatinine  $\geq 2.0$  mg/dL, diabetic foot) or macrovascular disease (coronary heart disease, history or presence of stroke, symptomatic peripheral vascular disease) were also recorded. Low-risk patients had no risk factor other than diabetes (n=1506), moderate-risk patients had any one of these risk factors (n=5425), and high-risk patients were participants with microvascular or macrovascular disease (n=1769).

Prescriptions were audited for various medications including lipid-lowering, antidiabetic, and antihypertensive drugs. We obtained details of type of statin (atorvastatin, rosuvastatin, other statins) and daily dose in mg/day. Frequency of prescription of fibrates (fenofibrate) was also obtained. Low-dose statin prescription was defined as atorvastatin <10 mg/day, simvastatin <20 mg/day, or rosuvastatin <5 mg/day; moderate dose as atorvastatin 10–20 mg/day, simvastatin 20–40 mg/day, or rosuvastatin 5–10 mg/day; and high dose as atorvastatin 40–80 mg/day or rosuvastatin 20–40 mg/day according to the ACC/AHA guidelines.<sup>8</sup>

*Statistical analyses.* All the data were computerized and quality checks were performed to reduce duplicate and redundant data. Statistical analyses were performed using SPSS for Windows (SPSS, V.13.0). Descriptive statistics are presented with unadjusted data and proportions. Intergroup comparisons were performed using  $\chi^2$  test. p Values <0.05 were considered significant.

## RESULTS

We obtained detailed prescriptions for 8699 patients with type 2 diabetes (men 5292, women 3407). Recruitment at different sites was Jaipur (3 sites, n=3714, 42.7%), Nagpur (n=1536, 17.7%), Madurai (n=971, 11.2%), Dibrugarh (n=796, 9.2%), Lucknow (n=792, 9.1%), Udaipur (n=548, 6.3%), and Jodhpur (n=342, 3.9%). Patients were subdivided according to level of care into the internists' group (n=2301, 26.5%), diabetologists' group (n=3299, 37.9%), and endocrinologists' group (n=3099, 35.6%). Demographic and clinical details of the study participants are shown in [table 1](#). Twelve per cent of the study participants were <40 years of age. Most of the patients had diabetes for >2 years and a third for >5 years. Risk factor details were available for most patients ([table 1](#)). Smoking and/or tobacco use was one-fifth while moderate-to-high physical activity in less than half. Hypertension was present in 51.5%, with total cholesterol  $\geq 200$  mg/dL in 34.9%, low-density lipoprotein cholesterol  $\geq 100$  mg/dL in 50.0%, triglycerides  $\geq 150$  mg/dL in 35.2%, and low HDL cholesterol in 48.9%. Hypothyroidism was present in 9.2% and was more in women (13.0%). Coronary heart disease was present in 15.4% and others (stroke, large vessel peripheral arterial disease in 5.2% while microvascular complications such as retinopathy,

**Table 1** Demographic and clinical characteristics of the study cohort

Variable	Numbers with data Total, men/women	Total (N=8699)	Men (N=5292)	Women (N=3407)	X2 test p value (male/female differences)
Age groups					
<40	8699, 5292/3407	1016 (11.7)	625 (11.8)	391 (11.5)	0.635
40–49		2288 (26.3)	1385 (26.2)	903 (26.5)	0.731
50–59		2815 (32.3)	1728 (32.6)	1087 (31.9)	0.466
60+		2580 (29.7)	1554 (29.3)	1026 (30.1)	0.558
Socioeconomic status					
Low	6346, 3766/2580	2239 (35.3)	1345 (35.7)	894 (34.6)	0.384
Middle		2516 (39.6)	1499 (39.8)	1017 (39.4)	0.758
High		1591 (25.1)	922 (24.5)	669 (25.9)	0.191
Diabetes duration (year)					
<2	5081, 3027/2054	948 (18.6)	554 (18.3)	394 (19.2)	0.429
2–5		2263 (44.5)	1340 (44.2)	923 (44.9)	0.638
>5		1870 (36.8)	1133 (37.4)	737 (35.9)	0.261
Smoking/tobacco use	7695, 4678/3017	1633 (21.2)	1201 (25.6)	432 (14.3)	<0.001
Physical activity	7029, 4372/2657	3150 (44.8)	2122 (48.5)	1028 (38.7)	<0.001
Obesity, BMI $\geq$ 25 kg/m <sup>2</sup>	8699, 5292/3407	3070 (35.3)	1773 (33.5)	1293 (37.9)	<0.001
Hypertension	8673, 5275/3398	4464 (51.5)	2583 (48.9)	1881 (55.3)	<0.001
Cholesterol $\geq$ 200 mg/dL	3979, 2469/1510	1390 (34.9)	824 (33.4)	566 (37.5)	0.008
LDL cholesterol $\geq$ 100 mg/dL	3979, 2469/1510	1989 (50.0)	1193 (48.3)	796 (52.7)	0.007
Triglycerides $\geq$ 150 mg/dL	3979, 2469/1510	1403 (35.2)	866 (35.0)	537 (35.5)	0.754
HDL <40/50 mg/dL	3979, 2469/1510	1945 (48.9)	1025 (41.5)	920 (60.9)	0.001
Macrovascular complications					
Coronary heart disease	7131, 4391/2740	1099 (15.4)	720 (16.4)	379 (13.8)	0.003
Others (stroke, PAD)		372 (5.2)	232 (8.5)	140 (5.1)	0.743
Microvascular diseases					
Retinopathy	4851, 2992/1859	298 (6.1)	183 (6.1)	115 (6.1)	0.994
Others		670 (13.9)	424 (14.2)	246 (13.2)	0.357
Hypothyroidism	5423, 3289/2134	500 (9.2)	222 (6.7)	278 (13.0)	<0.001
Chronic renal disease (serum creatinine $\geq$ 2.0 mg/dL)	6381, 3915/2466	356 (5.6)	267 (6.8)	89 (3.6)	<0.001

Numbers in parentheses are percent.

BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAD, peripheral arterial disease.

diabetic foot or advanced chronic renal disease (creatinine  $\geq$ 2.0 mg/dL) was in 6.1%, 13.9%, and 6.8%, respectively.

Use of lipid-lowering drugs and others is shown in [table 2](#). Statins were prescribed in 4802 (55.2%) patients, significantly more in men (57.2%) compared with women (52.1%;  $p<0.001$ ). Use of fibrates was low (9.2%). Insulins were used in 15.8%, more in men (16.8%) as compared with women (14.2;  $p=0.016$ ). Use of antihypertensive drugs is also shown in [table 2](#). The most frequently used drugs were renin angiotensin system blockers, ACE inhibitors, or angiotensin receptor blockers in 36.4% of patients, while diuretics (31.8%),  $\beta$ -blockers (27.6%), and calcium channel blockers (23.7%) were prescribed in lesser proportions.

Statin prescription was significantly greater by diabetologists (n=2126/3299, 64.4%) compared with internists (n=1227/2301, 53.3%) and endocrinologists (n=1449/3099, 46.8%;  $p<0.001$ ; [table 2](#)). It was also lower in patients <40 years of age (34.3%), compared with those aged 40–49 years (49.7%), 50–59 years (60.1%), or  $\geq$ 60 years (62.2%;  $p<0.001$ ; [figure 1](#)). Statin prescriptions

were significantly greater in high-risk patients (58.0%) compared with medium-risk (53.8%) and low-risk (56.8%) patients ( $p<0.001$ ; [table 2](#)).

Atorvastatin was the most prescribed statin (n=3560, 74.1% of statin prescriptions), as compared with rosuvastatin (n=1098, 22.9%) or others (simvastatin or pitavastatin; n=144, 3.0%). Of the patients prescribed statins (n=4802), high-dose statins (atorvastatin  $>20$  mg/day or rosuvastatin  $>10$  mg/day)<sup>8</sup> were in 610 (12.7%), moderate dose (atorvastatin 10–20 mg/day or rosuvastatin 5–10 mg/day)<sup>8</sup> in 4100 (85.4%) and low-dose (atorvastatin  $<10$  mg/day, rosuvastatin  $<5$  mg/day)<sup>8</sup> in 92 (1.9%; [table 2](#)). Use of high-dose statins was not significantly different in low-risk (13.5%), medium-risk (11.8%), or high-risk (14.5%) patient groups ([figure 2](#)).

## DISCUSSION


This multisite prescription audit and clinical study shows that statins are prescribed in  $<60\%$  of clinic-based patients with type 2 diabetes in India. High-dose statins, which are recommended in all the patients with

**Table 2** Prescription audit of drug therapies in the study cohort

Variable	Numbers with data Total, men/women	Total (N=8699)	Men (N=5292)	Women (N=3407)	$\chi^2$ test p value (male/female differences)
Antidiabetes drugs					
Insulin	5023, 3053/1970	794 (15.8)	513 (16.8)	281 (14.2)	0.016
Oral antidiabetics	8699, 5292/3407	4229 (84.2)	2772 (90.8)	1457 (73.9)	<0.001
Antihypertensive and other drugs					
Renin angiotensin system blockers	8699, 5292/3407	3169 (36.4)	1897 (35.8)	1272 (37.3)	0.159
$\beta$ -blockers	6258, 3898/2360	1726 (27.6)	1060 (27.2)	666 (28.2)	<0.001
Calcium channel blockers	4636, 2820/1816	1100 (23.7)	601 (21.3)	499 (27.5)	<0.001
Diuretics	4515, 2733/1782	1438 (31.8)	815 (29.8)	623 (34.9)	<0.001
Antiplatelets	6229, 4515/2733	2073 (33.3)	1332 (29.5)	741 (27.1)	0.029
Lipid-lowering drugs					
Statins	8699, 5292/3407	4802 (55.2)	3026 (57.2)	1776 (52.1)	<0.001
Fibrates	3546, 2132/1414	325 (9.2)	209 (9.8)	116 (8.2)	0.106
Lipid-lowering drugs at level of care	8699, 5292/3407				
Internists	2301, 1261/1040	1227 (53.3)	714 (56.6)	513 (49.3)	<0.001
Diabetologists	3299, 2215/1084	2126 (64.4)	1424 (64.3)	702 (64.3)	0.791
Endocrinologists	3099, 1816/1283	1449 (46.8)	888 (48.8)	561 (43.7)	0.004
Statins in various risk groups	8699, 5292/3407				
Low risk	1506, 940/566	855 (56.8)	539 (57.3)	316 (55.8)	0.567
Medium risk	5424, 3208/2216	2920 (53.8)	1806 (56.3)	1114 (50.3)	<0.001
High risk	1769, 1144/625	1027 (58.0)	681 (59.5)	346 (55.3)	0.089
Statin types as percent of statin use	4802, 3026/1776				
Atorvastatin		3560 (74.1)	2252 (74.4)	1308 (73.6)	0.554
Rosuvastatin		1098 (22.9)	687 (22.7)	411 (23.1)	0.726
Other statins		144 (3.0)	87 (2.9)	57 (3.2)	0.511
Statins dosage as percent of statin use	4802, 3026/1776				
Low dose		92 (1.9)	54 (1.8)	38 (2.1)	0.386
Moderate dose		4100 (85.4)	2580 (86.2)	1520 (85.6)	0.758
High dose		610 (12.7)	392 (13.0)	218 (12.3)	0.497

Numbers in parentheses are percent; renin angiotensin system blockers include ACE inhibitors and angiotensin receptor blockers.


**Figure 1** Statins in men and women with diabetes at different age groups show lower prescriptions at younger age groups.



diabetes,<sup>8</sup> are prescribed in less than one-sixth of patients prescribed statins. Although the prescriptions of statins are significantly greater in high-risk patients with diabetes, the overall prescriptions of statins as well as high-dose statins are suboptimal and much lower than the guidelines.<sup>8</sup>

Diabetes has long been considered a cardiovascular risk equivalent.<sup>22</sup> A Finnish study initially reported that patients with diabetes without manifest coronary heart disease had long-term (7-year) risk of events and mortality similar to patients without diabetes with manifest coronary heart disease.<sup>10</sup> Subsequently, a number of

**Figure 2** No significant differences in prescriptions of low-dose, moderate-dose, and high-dose statins in low-risk, medium-risk, and high-risk patients with diabetes. Low-risk patients had no cardiovascular risk factors—smoking/tobacco, hypertension; medium-risk patients had diabetes with any one of the above risk factors; and high-risk patients had diabetes with clinical evidence of microvascular or macrovascular disease.



observational studies in Australia and Europe reported similar associations.<sup>11 12</sup> Based on these studies, as well as randomized controlled trials that demonstrated lowering of coronary risk with statins in patients with diabetes,<sup>23</sup> the 2013 AHA/ACC guidelines on lipid management recommended that all patients with diabetes should receive high-dose statins irrespective of cholesterol levels.<sup>8</sup>

Registry-based studies in developed countries have reported increasing statin prescriptions in patients with type 2 diabetes since the guidelines endorsed their use. Prescriptions of statins in patients with diabetes have been reported in a few countries and examples include the Swedish National Diabetes Register,<sup>24</sup> US National Health and Nutrition Evaluation Surveys (NHANES),<sup>25</sup> British National Health Service (NHS),<sup>26</sup> and Australian general practice,<sup>27</sup> and the proportion of patients with diabetes prescribed statins varied from 25% to 65%. Studies have also reported that the prescriptions are significantly greater in diabetologists' practices (75%).<sup>26 27</sup> Targets are more than 90%.<sup>14</sup> In our study, statins were prescribed in 55% of patients and, although, are lower than the Swedish and Australian registries and NHANES where these drugs are prescribed in 70–90% of patients,<sup>24 25 27</sup> but, are higher than the British NHS-Check programme.<sup>26</sup> However, in our study, the high-dose statins are prescribed in less than a sixth of patients prescribed statins (12.7%) and this is clearly suboptimal. Moreover, our study shows that statin prescriptions are much lower than optimal in patients with type 2 diabetes with known cardiovascular disease (high-risk group, figure 2). It has been recommended that all patients with coronary heart disease should be on a statin.<sup>8 28</sup> We did not inquire regarding the intake of these drugs by the patients and this is a study limitation. It is well known that even after prescriptions, many patients do not take the statins and other medications for chronic diseases,<sup>29</sup> especially in India.<sup>30 31</sup>

The study has multiple strengths as well as limitations. This is one of the largest contemporary registries on diabetes management from India and is especially relevant because it was performed after the publication of AHA/ACC Lipid Guidelines.<sup>8</sup> Moreover, we have performed the study at clinics of qualified endocrinologists, as well as of diabetologists and internists who manage the majority of patients with diabetes in India.<sup>32</sup> Limitations of the study include lower proportions of patients from the southern and eastern regions of the country and greater proportions from the northern and western regions, non-representation of secondary and primary care physicians who treat the majority of patients with diabetes in India, lack of systematic collection data on microvascular complications (especially renal disease), pragmatic risk classification of the patients which is different from the suggested criteria,<sup>33</sup> and lack of patient-level consumption and adherence data. Other limitations include absence of baseline cholesterol levels of these patients to justify high-dose therapies and lack of data on the side effect profile of statins. Moreover, we did not perform a qualitative study to determine causes of low prescriptions of statins by physicians.

In conclusion, this study shows that prescriptions of statins in clinic-based patients with type 2 diabetes in India are suboptimal. Efforts to increase use of these drugs to all patients with diabetes to prevent cardiovascular complications are urgently required. These results are all the more important after the publication of the HOPE-3 study where statin use has been associated with a significant decrease in cardiovascular mortality and acute events in intermediate-risk patients including those with diabetes.<sup>34</sup> Strategies to optimize prescriptions are better clinician awareness of guidelines and continuing medical education as well as periodic prescription audits and dissemination of results to improve quality of preventive care among patients with type 2 diabetes.

## Author affiliations

<sup>1</sup>Departments of Preventive Cardiology, Internal Medicine and Endocrinology, Eternal Heart Care Centre and Research Institute, Mount Sinai New York Affiliate, Jaipur, Rajasthan, India

<sup>2</sup>Research Unit, Fortis Escorts Hospital, Jaipur, Rajasthan, India

<sup>3</sup>Department of Endocrinology, Galaxy Specialty Centre, Jaipur, Rajasthan, India

<sup>4</sup>Department of Diabetes, Diabetes Care and Research Centre, Nagpur, Maharashtra, India

<sup>5</sup>Department of Diabetes, Madurai Medical College, Madurai, Tamil Nadu, India

<sup>6</sup>Department of Medicine, Assam Medical College, Dibrugarh, Assam, India

<sup>7</sup>Department of Medicine, BBD College of Dental Sciences, Lucknow, Uttar Pradesh, India

<sup>8</sup>Department of Endocrinology, RNT Medical College, Udaipur, Rajasthan, India

<sup>9</sup>Department of Medicine, Satyam Hospital, Jodhpur, Rajasthan, India

**Contributors** RG conceived and designed the study, researched the data, and wrote and edited the manuscript. SL, KKS, SKS, SG, and RSK contributed to intellectual discussion and reviewed and edited the manuscript. SL, KKS, SKS, SG, AJA, BNM, AM, DCS, and ASM researched the data. RG is the guarantor.

**Competing interests** None declared.

**Patient consent** Obtained.

**Ethics approval** Institutional Ethics Committee, Eternal Heart Care Centre and Research Institute, Mount Sinai New York Affiliate, Jaipur, India.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

## REFERENCES

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet* 2016;387:1513–30.
2. Chowdhury TA, Lasker SS. Complications and cardiovascular risk factors in South Asians and Europeans with early-onset type 2 diabetes. *QJM* 2002;95:241–6.
3. Misra A, Ramchandran A, Jayawardena R, *et al*. Diabetes in South Asians. *Diabet Med* 2014;31:1153–62.
4. Gupta A, Gupta R, Sharma KK, *et al*. Prevalence of diabetes and cardiovascular risk factors in middle-class urban populations in India. *BMJ Open Diab Res Care* 2014;2:e000048.
5. Deepa M, Bhansali A, Anjana RM, *et al*. Knowledge and awareness of diabetes in urban and rural India: the Indian Council of Medical Research India Diabetes Study (Phase I): Indian Council of Medical Research India Diabetes 4. *Indian J Endocrinol Metab* 2014;18:379–85.
6. Gupta R, Sharma KK, Gupta BK, *et al*. Education status related disparities in awareness, treatment and control of cardiovascular risk factors in India. *BMJ Heart Asia* 2015;7:1–6.
7. Sattar N, Gill JMR. Type 2 diabetes in migrant South Asians: mechanisms, mitigation and management. *Lancet Diab Endocrinol* 2015;3:1004–16.
8. Stone NJ, Robinson JG, Lichtenstein AH, *et al*. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. *Circulation* 2014;129:S1–45.
9. Stamler J, Vaccaro O, Neaton JD, *et al*. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 1993;16:434–44.
10. Haffner SM, Lehto S, Ronnena T, *et al*. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998;339:229–34.
11. Barr EL, Zimmet PZ, Welborn TA, *et al*. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). *Circulation* 2007;116:151–7.
12. Rana JS. Is diabetes really a CHD risk equivalent? [http://www.acc.org/latest-in-cardiology/articles/2017/04/12/13/40/is-diabetes-really-a-chd-risk-equivalent?wt.mc\\_id=twitter](http://www.acc.org/latest-in-cardiology/articles/2017/04/12/13/40/is-diabetes-really-a-chd-risk-equivalent?wt.mc_id=twitter) (accessed 1 Mar 2016).
13. Reiner Z, Catapano AL, De Backer G, *et al*. European Association for Cardiovascular Prevention and Rehabilitation, ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J* 2011;32:1769–818.
14. Handelsman Y, Bloomgarden ZT, Grunberger G, *et al*. American association of clinical endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. *Endocr Pract* 2015;21 (Suppl 1):1–87.
15. Fox CS, Golden SH, Anderson C, *et al*. American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Clinical Cardiology Council on Cardiovascular and Stroke Nursing, *et al*. Update on the prevention of cardiovascular disease in adults with type-2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. *Diabetes Care* 2015;38:1777–803.
16. Eliasson B, Svensson AM, Miftaraj M, *et al*. Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus—an observational study from the Swedish National Diabetes Register. *PLoS ONE* 2011;6:e18744.
17. Raheja BS, Kapur A, Bhoraskar A, *et al*. DiabCare Asia-India Study: diabetes care in India—current status. *J Assoc Physicians India* 2001;49:717–22.
18. Goyal P, Sharma G, Bal BS, *et al*. Prospective, noninterventional, uncontrolled, open-chart, pharmacoepidemiologic study of prescribing patterns for lipid-lowering drugs at a tertiary care teaching hospital in North India. *Clin Ther* 2002;24:2064–76.
19. Nagpal J, Bhartia A. Quality of diabetes care in the middle and high income group populace: the Delhi Diabetes Community (DEDICOM) Survey. *Diabetes Care* 2006;29:2341–8.
20. Sharma N, Sharma SK, Maheshwari VD, *et al*. Association of low educational status with microvascular complications in type 2 diabetes: Jaipur Diabetes Registry-1. *Indian J Endocrinol Metab* 2015;19:327–32.
21. Joshi SR. Diabetes care in India. *Ann Global Health* 2015;81:830–8.
22. Grundy SM, Benjamin IJ, Burke GL, *et al*. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. *Circulation* 1999;100:1134–46.
23. Baigent C, Blackwell L, Emberson J, *et al*. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. *Lancet* 2010;376:1670–81.
24. Gudbjörnsdóttir S, Eeg-Olofsson K, Cederholm J, *et al*. Swedish National Diabetes Register (NDR). Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR). *Diabet Med* 2009;26:53–60.
25. Mann DM, Woodward M, Ye F, *et al*. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. *Arch Intern Med* 2009;169:1718–20.
26. Chang KC, Soljak M, Lee JT, *et al*. Coverage of a national cardiovascular risk assessment and management programme (NHS Health Check): retrospective database study. *Prev Med* 2015;78:1–8.
27. Jiwa M, Meng X, Sriram D, *et al*. The management of Type 2 diabetes: a survey of Australian general practitioners. *Diabetes Res Clin Pract* 2012;95:326–32.
28. Smith SC, Benjamin EJ, Bonow RO, *et al*. AHA/ACC secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. *J Am Coll Cardiol* 2011;58:2432–46.

29. Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med* 2005;353:487–97.
30. Choudhry NK, Dugani SB, Shrank WH, *et al*. Despite increased use and sales of statins in India, per capita prescription rates remain far below high-income countries. *Health Affairs* 2014;33:273–82.
31. Xavier D, Gupta R, Sigamani A, *et al*. Community health worker based intervention for adherence to medications and lifestyle modifications after acute coronary syndrome: a randomized controlled trial. *Lancet Diab Endocrinol* 2016;4:244–53.
32. Sharma KK, Gupta R, Agrawal A, *et al*. Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India. *Vasc Health Risk Manag* 2009;5:1007–14.
33. Russel KG, Rosenzweig J. Improving outcomes for patients with diabetes using Joslin Diabetes Center's registry and risk stratification system. *J Health Informat Manag* 2007;21:26–33.
34. Yusuf S, Bosch J, Dagenias G, *et al*, HOPE-3 Investigators. Cholesterol lowering in intermediate risk persons without cardiovascular disease. *N Engl J Med* 2016;374:2021–31.